Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
30.07.25 | 14:18
111,70 Euro
-0,71 % -0,80
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
111,70112,2018:07
111,70112,3018:07

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIpsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 20251
IPSEN Aktie jetzt für 0€ handeln
DoExelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors344- Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo...
► Artikel lesen
DoIpsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors3
DoIpsen Pharma: Cabometyx approved in the EU for previously treated advanced neuroendocrine tumors332Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous...
► Artikel lesen
23.07.Ipsen Updates Executive Committee1
23.07.Ipsen Pharma: Ipsen announces changes to its Executive Committee469PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele...
► Artikel lesen
22.07.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 20251
16.07.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 20254
10.07.Ipsen Pharma: Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital1
08.07.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 20251
07.07.Ipsen Pharma: Ipsen - Half year statement - 2025 06 30306Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, 07 JULY 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN...
► Artikel lesen
01.07.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 20253
01.07.EQS-News: Ipsen Pharma GmbH: Gemeinsam für eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Community Day 2025 für Menschen und Umwelt408EQS-News: Ipsen Pharma GmbH / Schlagwort(e): Sonstiges Gemeinsam für eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Community Day 2025 für Menschen und Umwelt 01.07.2025...
► Artikel lesen
26.06.Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours4
24.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 20251
20.06.Madrigal, Ipsen, SpringWorks get EU backing for their drugs2
20.06.CHMP Issues Positive Opinion On Ipsen's Cabometyx For Advanced PNET And EpNET Patients1
20.06.Exelixis, Inc.: Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors452- A regulatory decision by the European Medicines Agency is anticipated in 2025 - - In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting - Exelixis, Inc....
► Artikel lesen
20.06.Ipsen Pharma: Ipsen receives positive CHMP opinion for Cabometyx in previously treated advanced neuroendocrine tumors569If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin...
► Artikel lesen
17.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 20251
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1